Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
13
10
2020
accepted:
22
10
2020
pubmed:
11
11
2020
medline:
3
3
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Immune thrombocytopenia (ITP) is now well-known to reduce patients' health-related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I-WISh (ITP World Impact Survey) was an exploratory, cross-sectional survey designed to establish the multifaceted impact of ITP, and its treatments, on patients' lives. It focused on perceptions of 1507 patients and 472 physicians from 13 countries regarding diagnostic pathway, frequency and severity of signs and symptoms, and treatment use. Twenty-two percent of patients experienced delayed diagnosis (caused by several factors), 73% of whom felt anxious as a result. Patients rated fatigue among the most frequent, severe symptom associated with ITP at diagnosis (58% most frequent; 73% most severe), although physicians assigned it lower priority (30%). Fatigue was one of the few symptoms persisting at survey completion (50% and 65%, respectively) and was the top symptom patients wanted resolved (46%). Participating physicians were experienced at treating ITP, thereby recognizing the need to limit corticosteroid use to newly-diagnosed or first-relapse patients and espoused increased use of thrombopoietin receptor agonists and anti-CD20 after relapse in patients with persistent/chronic disease. Patient and physicians were largely aligned on diagnosis, symptoms, and treatment use. I-WISh demonstrated that patients and physicians largely align on overall ITP symptom burden, with certain differences, for example, fatigue. Understanding the emotional and clinical toll of ITP on the patient will facilitate shared decision-management, setting and establishment of treatment goals and disease stage-appropriate treatment selection.
Identifiants
pubmed: 33170956
doi: 10.1002/ajh.26045
pmc: PMC7898610
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-198Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Lancet. 2011 Jan 29;377(9763):393-402
pubmed: 20739054
Lancet. 2009 Feb 21;373(9664):641-8
pubmed: 19231632
J Thromb Haemost. 2015 Mar;13(3):457-64
pubmed: 25495497
J Thromb Haemost. 2010 Jun;8(6):1372-82
pubmed: 20230419
Eur J Haematol. 2009 Sep;83(3):175-82
pubmed: 19374704
Blood. 2008 Aug 15;112(4):999-1004
pubmed: 18463354
Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520
pubmed: 23714309
Blood. 2013 Jan 17;121(3):537-45
pubmed: 23169778
Am J Hematol. 2016 Oct;91(10):995-1001
pubmed: 27351715
Am J Hematol. 2015 Mar;90(3):E40-3
pubmed: 25400215
N Engl J Med. 2007 Nov 29;357(22):2237-47
pubmed: 18046028
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
Eur J Haematol. 2017 Apr;98(4):371-377
pubmed: 27981682
Br J Haematol. 2020 Oct;191(1):98-106
pubmed: 32501532
Br J Haematol. 2014 Jun;165(6):865-9
pubmed: 24725224
Blood Adv. 2019 Dec 10;3(23):3829-3866
pubmed: 31794604
Intern Med. 2016;55(17):2379-85
pubmed: 27580537
Br J Haematol. 2004 Apr;125(2):232-9
pubmed: 15059147
Br J Haematol. 2016 Jan;172(2):262-73
pubmed: 26537623
Am J Hematol. 2021 Feb 1;96(2):199-207
pubmed: 33107998
Blood. 2017 Dec 7;130(23):2527-2536
pubmed: 29042367
Br J Haematol. 2015 Jul;170(2):141-9
pubmed: 25823426
Am J Hematol. 2021 Feb 1;96(2):188-198
pubmed: 33170956
Ann Hematol. 2002 Aug;81(8):436-40
pubmed: 12224000
Blood. 2010 Jan 14;115(2):168-86
pubmed: 19846889
Br J Haematol. 2014 Oct;167(2):243-51
pubmed: 25041261
Am J Hematol. 2018 Jul;93(7):921-930
pubmed: 29696684
Blood. 2009 Mar 12;113(11):2386-93
pubmed: 19005182
N Engl J Med. 2010 Nov 11;363(20):1889-99
pubmed: 21067381
Br J Haematol. 2017 Apr;177(1):39-54
pubmed: 28295192
Transfusion. 2013 Nov;53(11):2807-12
pubmed: 23451917
Haematologica. 2019 Jun;104(6):1124-1135
pubmed: 31126963
J Thromb Haemost. 2012 Oct;10(10):1988-98
pubmed: 22863415
Blood Adv. 2017 Nov 28;1(25):2414-2420
pubmed: 29296891
Semin Hematol. 2013 Jan;50 Suppl 1:S83-8
pubmed: 23664524
Blood. 2012 Jun 21;119(25):5989-95
pubmed: 22566601
Lancet. 2008 Feb 2;371(9610):395-403
pubmed: 18242413
Blood. 2012 Aug 2;120(5):960-9
pubmed: 22740443
Br J Haematol. 2013 May;161(3):411-23
pubmed: 23432528
Lancet. 2015 Apr 25;385(9978):1653-61
pubmed: 25662413